Federal Register / Vol. 88, No. 177 / Thursday, September 14, 2023 / Notices 63115 

ESTIMATED ANNUALIZED BURDEN TABLE

Form Type of respondent Number of 

respondents 

Number 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

hours 

Partners and sustainability ................ All TPP grantees .............................. 90 2 15/60 45 

Training ............................................. All TPP Grantees ............................. 90 2 15/60 45 

Dissemination .................................... All TPP Grantees ............................. 90 2 30/60 90 

Stakeholder Engagement ................. All TPP Grantees ............................. 90 2 15/60 45 

Reach and Demographics ................ Tier 1 and Tier 2 Phase II Grantees 64 2 3 384 

Dosage .............................................. Tier 1 and Tier 2 Phase II Grantees 64 2 2 256 

Fidelity and Quality ........................... Tier 1 and Tier 2 Phase II Grantees 64 2 2 256 

Tier 2 Innovation Network ................. Tier 2 Innovation Network Grantees 14 2 15/60 7 

Supportive Services (Tier 1) ............. Tier 1 Grantees ................................ 54 2 15/60 27 

Total ........................................... ........................................................... ........................ 2 ........................ 1,155 

Sherrette A. Funn, 

Paperwork Reduction Act Reports Clearance 

Officer, Office of the Secretary. 

[FR Doc. 2023–19848 Filed 9–13–23; 8:45 am] 

BILLING CODE 4168–11–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Heart, Lung, and 

Blood Initial Review Group; NHLBI 

Mentored Patient-Oriented Research Study 

Section. 

Date: October 26–27, 2023. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge I, 6705 Rockledge Drive, Bethesda, 

MD 20892 (Virtual Meeting). 

Contact Person: Fungai Chanetsa, Ph.D., 

MPH, Scientific Review Officer, Office of 

Scientific Review/DERA, National Heart, 

Lung, and Blood Institute, National Institutes 

of Health, 6705 Rockledge Drive, Room 206– 

B, Bethesda, MD 20817, (301) 402–9394. 

fungai.chanetsa@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–19907 Filed 9–13–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Heart, Lung, and 

Blood Initial Review Group; Clinical Trials 

Review Study Section. 

Date: October 23, 2023. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: North Bethesda Marriott Hotel & 

Conference Center, Montgomery County 

Conference Center Facility, 5701 Marinelli 

Road, North Bethesda, MD 20852. 

Contact Person: Keary A Cope, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, National Institutes of Health, 

6705 Rockledge Drive, Room 209–A, 

Bethesda, MD 20892–7924, (301) 827–7912, 

copeka@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: September 11, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–19905 Filed 9–13–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Heart, Lung, and 

Blood Initial Review Group; NHLBI SingleSite and Pilot Clinical Trials Study Section. 

Date: October 25–26, 2023. 

Time: 8:30 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites at the Chevy Chase 

Pavilion, 4300 Military Road NW, 

Washington, DC 20015. 


lotter on DSK11XQN23PROD with NOTICES1
63116 Federal Register / Vol. 88, No. 177 / Thursday, September 14, 2023 / Notices 

Contact Person: YingYing Li-Smerin, MD, 

Ph.D., Scientific Review Officer, Office of 

Scientific Review/DERA, National Heart, 

Lung, and Blood Institute, 6705 Rockledge 

Drive, Room 207–P, Bethesda, MD 20892– 

7924, 301–827–7942, lismerin@nhlbi.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: September 11, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–19902 Filed 9–13–23; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Heart, Lung, 

and Blood Advisory Council. 

The meeting will be a hybrid meeting 

held in-person and virtually and will be 

open to the public as indicated below. 

Individuals who plan to attend inperson or view the virtual meeting and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. The meeting 

can be accessed from the NIH Videocast 

at the following links: http://

videocast.nih.gov/ or https://

www.nhlbi.nih.gov/about/advisory-andpeer-review-committees/advisorycouncil. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Advisory Council. 

Date: October 24, 2023. 

Closed: 9:00 a.m. to 10:00 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge I, 6705 Rockledge Drive, Bethesda, 

MD 20892 (Hybrid Meeting). 

Open: 10:00 a.m. to 5:00 p.m. 

Agenda: To discuss program policies and 

issues. 

Place: National Institutes of Health, 

Rockledge I, 6705 Rockledge Drive, Bethesda, 

MD 20892 (Hybrid Meeting). 

Virtual Access: http://videocast.nih.gov/or 

https://www.nhlbi.nih.gov/about/advisoryand-peer-review-committees/advisorycouncil. Please note, the link to the videocast 

meeting will be posted within a week of the 

meeting date. 

Contact Person: Laura K. Moen, Ph.D., 

Director, Division of Extramural Research 

Activities, National Heart, Lung, and Blood 

Institute, National Institutes of Health, 6705 

Rockledge Drive, Room 206–Q, Bethesda, MD 

20892, 301–827–5517, moenl@mail.nih.gov. 

Any member of the public interested in 

presenting oral comments to the committee 

may notify the Contact Person listed on this 

notice at least 10 days in advance of the 

meeting. Interested individuals and 

representatives of organizations may submit 

a letter of intent, a brief description of the 

organization represented, and a short 

description of the oral presentation. Only one 

representative of an organization may be 

allowed to present oral comments and if 

accepted by the committee, presentations 

may be limited to five minutes. Both printed 

and electronic copies are requested for the 

record. In addition, any interested person 

may file written comments with the 

committee by forwarding their statement to 

the Contact Person listed on this notice. The 

statement should include the name, address, 

telephone number and when applicable, the 

business or professional affiliation of the 

interested person. 

In the interest of security, NIH has 

procedures at https://www.nih.gov/aboutnih/visitor-information/campus-accesssecurity for entrance into on-campus and offcampus facilities. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors attending a meeting on 

campus or at an off-campus federal facility 

will be asked to show one form of 

identification (for example, a governmentissued photo ID, driver’s license, or passport) 

and to state the purpose of their visit. 

Information is also available on the 

Institute’s/Center’s home page: 

www.nhlbi.nih.gov/meetings/nhlbac/ 

index.htm, where an agenda and any 

additional information for the meeting will 

be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: September 11, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–19906 Filed 9–13–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Docket ID FEMA–2023–0002; Internal 

Agency Docket No. FEMA–B–2369] 

Proposed Flood Hazard 

Determinations 

AGENCY: Federal Emergency 

Management Agency, Department of 

Homeland Security. 

ACTION: Notice. 

SUMMARY: Comments are requested on 

proposed flood hazard determinations, 

which may include additions or 

modifications of any Base Flood 

Elevation (BFE), base flood depth, 

Special Flood Hazard Area (SFHA) 

boundary or zone designation, or 

regulatory floodway on the Flood 

Insurance Rate Maps (FIRMs), and 

where applicable, in the supporting 

Flood Insurance Study (FIS) reports for 

the communities listed in the table 

below. The purpose of this notice is to 

seek general information and comment 

regarding the preliminary FIRM, and 

where applicable, the FIS report that the 

Federal Emergency Management Agency 

(FEMA) has provided to the affected 

communities. The FIRM and FIS report 

are the basis of the floodplain 

management measures that the 

community is required either to adopt 

or to show evidence of having in effect 

in order to qualify or remain qualified 

for participation in the National Flood 

Insurance Program (NFIP). 

DATES: Comments are to be submitted 

on or before December 13, 2023. 

ADDRESSES: The Preliminary FIRM, and 

where applicable, the FIS report for 

each community are available for 

inspection at both the online location 

https://hazards.fema.gov/femaportal/ 

prelimdownload and the respective 

Community Map Repository address 

listed in the tables below. Additionally, 

the current effective FIRM and FIS 

report for each community are 

accessible online through the FEMA 

Map Service Center at https://

msc.fema.gov for comparison. 

You may submit comments, identified 

by Docket No. FEMA–B–2369, to Rick 

Sacbibit, Chief, Engineering Services 

Branch, Federal Insurance and 

Mitigation Administration, FEMA, 400 

C Street SW, Washington, DC 20472, 

(202) 646–7659, or (email) 

patrick.sacbibit@fema.dhs.gov. 

FOR FURTHER INFORMATION CONTACT: Rick 

Sacbibit, Chief, Engineering Services 

Branch, Federal Insurance and 


lotter on DSK11XQN23PROD with NOTICES1